Oncology Institute (TOIIW) Income from Continuing Operations (2020 - 2026)

Oncology Institute has reported Income from Continuing Operations for 7 years, with the latest figure at 2492000.0 in Q1 2026.

• For the quarter ending Q1 2026, Income from Continuing Operations rose 87.28% year-over-year to 2492000.0; the trailing twelve-month figure through Mar 2026 stood at 43513000.0 (up 32.39% YoY), and the FY2025 full-year result was 60606000.0, up 6.27% from the prior year.
• Income from Continuing Operations for Q1 2026 stood at 2492000.0, up from 7508000.0 in the prior quarter.
• The five-year high for Income from Continuing Operations was 19286000.0 in Q1 2022, with the low at 29998000.0 in Q1 2023.
• Historically, Income from Continuing Operations has averaged 12392764.71 across 5 years, with a median of 16113000.0 in 2024.
• Annual changes were most pronounced in 2022 — Income from Continuing Operations soared 2036.35% — and 2023, when it slumped 551.42%.
• Oncology Institute's Income from Continuing Operations stood at 11007000.0 in 2022, then plunged by 70.38% to 18754000.0 in 2023, then increased by 29.71% to 13182000.0 in 2024, then jumped by 43.04% to 7508000.0 in 2025, then soared by 66.81% to 2492000.0 in 2026.
• The last three Income from Continuing Operations figures came in at 2492000.0 (Q1 2026), 7508000.0 (Q4 2025), and 16504000.0 (Q3 2025), per Business Quant data.